Naphthyridine integrase inhibitors

1. A compound of formula (I)

wherein R 1 is selected from 1,2-thiazinan-2-yl optionally substituted with one or more substituents independently selected from group consisting of halogen, hydroxy, C 1-8 alkyl, C 1-8 haloalkyl, —OR 3 , —SR 3 , —CN, hydroxy, oxo, —R 3 C(O)N(R 4 ) 2 , —C(O)N(R 4 ) 2 , —R 3 C(O)R 4 , —R 3 OR 3 OH, —C(O)R 4 , —N(R 4 )C(O)R 4 , —N(R 4 )C(O)R 4 , —R 3 N(R 4 )C(O)R 4 , —N(R 4 ) 2 , —R 3 N(R 4 ) 2 , C 6-14 aryl, C 6-14 aryloxy, and R 3 optionally substituted with C 6-14 aryl;

R 2 is C 3-6 cycloalkyl, or C 6-14 aryl optionally substituted with one or more substituents independently selected from the group consisting of hydrogen, halogen, hydroxy, C 1-8 alkyl, —OR 5 , and NR 5 R 6 ;

R 3 is C 1-8 alkyl, C 3-6 cycloalkyl, haloC 1-8 alkyl, C 2-6 alkenyl, C 3-6 cycloalkenyl, or C 3-6 alkenyl;

R 4 is hydrogen, C 1-8 alkyl, C 3-8 cycloalkyl, C 1-6 haloalkyl, C 6-14 aryl, C 6-14 aralkyl, C 2-6 alkenyl, or C 3-6 cycloalkenyl, C 3-6 alkynyl;

R 5 and R 6 are independently selected from the group consisting of hydrogen, C 1-8 haloalkyl, C 1-8 alkylC 3-6 cycloalkyl, C 6-14 aryl, C 6-14 aralkyl, —C(O) m R 7 , —C(O)C(O) m R 7 , and Y optionally substituted with one or more —OR 7 , —C(O) m R 7 , —S(O) n R 7 , —S(O) n R 7 , —C(O)C(O) m R 7 ,

R 7 is hydrogen, C 1-8 alkyl, C 3-6 cycloalkyl, —Ycycloalkyl, —YOH, —Y(OY) w where w is 1-10;

m is 1 or 2;

n is 0, 1, or 2;

p is 0, or 1;

A is 1,3,4-oxadiazolyl;

Q is C 1-3 alkyl, —NR 4 , —O—, —C(O), —C(OR 4 )—, S(O) 2 , or —CF 2 ;

Y is a C 1-5 al kylene chain, wherein said C 1-5 alkylene chain is optionally subsituted by one or more groups independently selected from ═O, ═S, and halo, and wherein said C 1-5 alkylene chain optionally contains 1-3 heteroatoms selected from oxygen, sulfur, and nitrogen;

or pharmaceutically acceptable salt thereof.

2. 5-(1,1-Dioxido-1,2-thiazinan-2-yl)-7[5-(4-fluorobenzyl)-1,3,4-oxadiazol-2-yl]-1,6-naphthyridin-8-ol or pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 together with a pharmaceutically acceptable carrier.

4. A pharmaceutical composition according to claim 3 in the form of a tablet or capsule.

5. A pharmaceutical composition according to claim 3 in the form of a liquid or suspension.

6. A pharmaceutical composition comprising an effective amount of a compound according to claim 2 together with a pharmaceutically acceptable carrier.

7. A pharmaceutical composition according to claim 6 in the form of a tablet or capsule.

8. A pharmaceutical composition according to claim 6 in the form of a liquid or suspension.

9. A method of treatment of an HIV infection in a human comprising administering to said human an antiviral effective amount of a compound according to claim 2 .

10. A method of treatment of an HIV infection in a human comprising administering to said human an antiviral effective amount of a compound according to claim 1 .